A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)
This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
First received: August 8, 2008
Last updated: May 4, 2015
Last verified: May 2015
This study examined the safety and effectiveness of long-term administration of mometasone nasal spray in patients with perennial allergic rhinitis. Patients received mometasone for 12 weeks plus an additional 12 weeks if patient agreed to continue. Dose of mometasone could be decreased or increased during the study based on patient's response.
Perennial Allergic Rhinitis
Drug: Mometasone furoate
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis
Primary Outcome Measures:
- Change from Baseline in 4 nasal symptom score. [ Time Frame: All visits starting 2 weeks prior to treatment until 5 to 9 days after last administration of treatment ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Individual nasal symptom scores (sneezing, attack, rhinorrhea, nasal congestion, and nasal itching) [ Time Frame: All visits starting 2 weeks prior to treatment until 5 to 9 days after last administration of treatment ] [ Designated as safety issue: No ]
- Overall improvement (combination of nasal symptoms and rhinoscopic nasal findings) [ Time Frame: All visits during which patient is receiving drug (includes the 12 week drug administration period plus the 12 week additional drug administration period) ] [ Designated as safety issue: No ]
- Adverse events [ Time Frame: Throughout the study once initial treatment has started and until 5 to 9 days after last administration of treatment. ] [ Designated as safety issue: Yes ]
- Laboratory tests [ Time Frame: At baseline, and 4, 12, and 24 weeks after treatment ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||January 2006 (Final data collection date for primary outcome measure)
Experimental: Mometasone Nasal Spray
Open-label. Two sprays per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
Drug: Mometasone furoate
Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
|Ages Eligible for Study:
||16 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Moderate to severe perennial allergic rhinitis, >16 years of age
- Patients with coexisting tuberculous disease or lower respiratory tract infection and patients who have acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis judged by the investigator to require treatment
- Patients with coexisting infections or systemic mycosis for which there are no effective treatment
- Patients with coexisting mycosis in the nasal and paranasal cavities
- Patients who are judged to require prohibited concomitant drugs during the clinical study
- Patients who have experienced recent nasal septum ulcers, nasal surgery, or nasal trauma, which have not yet healed
- Patients with a history of hypersensitivity to steroids or mometasone furoate
- Patients who are pregnant or nursing or who may be pregnant and patients or whose partner desires to become pregnant during the study period
- Patients with severe hepatic disorder, renal disorder, cardiac disease, diabetes mellitus, hypertension, or hematological disease or other serious coexisting diseases and whose general condition is poor as judged by the investigators.
- Patients allergic to pollen and the pollen release season occurs in the 7 days before the start of treatment
- Patients diagnosed with vasomotor rhinitis or eosinophilic rhinitis
- Patients with nasal conditions which may interfere with efficacy evaluation of the study drug
- Patients who develop a disease which may affect nasal symptoms in the 7 days before the start of treatment
- Patients who are participating or have participated in a clinical trial of an investigational drug within 120 days before the day of obtaining informed consent
- Patients for whom the period of discontinuation of previous treatment before the start of study drug administration indicated Table 2 is not adequate or who cannot avoid the use of these drugs
- Patients undergoing specific desensitization therapy or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who had discontinued such therapy within 90 days prior to obtaining informed consent. (However, patients need not be excluded if therapy has been ongoing for at least 180 days before obtaining informed consent and maintenance therapy is now being conducted.)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
T. Ishikawa et. al; Practica otologica. Suppl. 122 Page1-17(2008.11) -Japanese language journal
||Merck Sharp & Dohme Corp.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 8, 2008
||May 4, 2015
||Japan: Pharmaceuticals and Medical Devices Agency
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on June 30, 2015
Rhinitis, Allergic, Perennial
Immune System Diseases
Respiratory Tract Diseases
Respiratory Tract Infections